Twist Bioscience Appoints Mark Buck as Senior Vice President, Operations
03 Outubro 2023 - 9:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the appointment of
Mark Buck as senior vice president, operations. Mr. Buck brings
experience improving manufacturing efficiency and driving revenue
and margin through managing supply chain and operations, including
planning, quality, procurement and logistics.
“Building on the foundation of his time serving in the United
State Marine Corps and drawing from military efficiency, Mark has
established a career in industry developing and optimizing
operational processes and requirements that enable scale for
multiple product groups across global geographies,” said Emily M.
Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We now
have two manufacturing sites and are making excellent progress in
the final steps of preparation for the launch of fast genes in
November, with a current median production turnaround time of six
business days, well under our current ten business day turnaround
time for standard speed genes. We look forward to Mark’s expertise
and strategic guidance as we continue to expand our reach and
market share globally.”
“Twist has the cultural foundation and the right teams in place
for the next phase of growth. I look forward to drawing on my
experience enhancing efficiency and productivity by integrating
teams and processes to drive toward profitability,” said Mr. Buck.
“I am eager to return to the life science industry at Twist and
play a role in enabling our customers to improve health and
sustainability.”
Prior to joining Twist, Mr. Buck served as corporate senior vice
president, operations, global supply chain at Excelitas
Technologies Corporation where he established a global footprint,
drove global supply chain optimization measures, enabled scale up
and drove revenue growth. His responsibilities included global
supply chain planning, global sourcing and procurement supply,
internal supply, supply quality and logistics inbound and outbound
movement of freight. Prior to Excelitas, Mr. Buck was director,
global supply chain management and general manager of resale
product operations at Bio-Rad, Inc., where he managed buy-sell
products, which grew in revenue to $270 million, significantly
improving profitability over his time in the role. He previously
held leadership positions including vice president operations,
global manufacturing, supply chain and logistics at Celerity Group;
director, operations management at Solectron corporation; and
senior supply chain operations manager at Apple Computer, Inc.
Before joining industry, Mr. Buck served in the United States
Marine Corps. He holds an MBA from National University and a B.S.
in electrical and computer engineering from University of Illinois,
Urbana-Champaign.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including statements regarding the planned launch of the
Fast Genes product and market share expansion, are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements involve known and unknown risks, uncertainties, and
other important factors that may cause Twist Bioscience’s actual
results, performance, or achievements to be materially different
from any future results, performance, or achievements expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the ability to achieve the
expected benefits of Twist Bioscience’s workforce reduction and
reduced investments in DNA data storage; the ability to attract new
customers and retain and grow sales from existing customers; the
ability of Twist to achieve sufficient revenue to achieve or
maintain positive cash flow from operations or profitability in any
given period; risks and uncertainties of rapidly changing
technologies and extensive competition in synthetic biology that
could make the products Twist Bioscience is developing obsolete or
non-competitive; uncertainties of the retention of significant
customers; the ability of Twist Bioscience to successfully
integrate acquired companies and to achieve expected benefits from
acquisitions; supply chain and other disruptions caused by the
COVID-19 pandemic or otherwise; risks of third party claims
alleging infringement of patents and proprietary rights or seeking
to invalidate Twist Bioscience’s patents or proprietary rights; and
the risk that Twist Bioscience’s proprietary rights may be
insufficient to protect its technologies. For a description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to Twist Bioscience’s business in general, see
Twist Bioscience’s risk factors set forth in Twist Bioscience’s
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on August 7, 2023 and subsequent filings with
the SEC. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Twist Bioscience
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231003145959/en/
For Twist Bioscience: Angela Bitting SVP, Corporate
Affairs 925-202-6211 abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024